Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAMIS PHARMACEUTICALS CORPORATION

(ADMP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ADAMIS PHARMACEUTICALS CORP : Submission of Matters to a Vote of Security Holders (form 8-K)

07/19/2021 | 04:08pm EDT

Item 5.07 Submission of Matters to a Vote of Security Holders.

At the annual meeting of stockholders of Adamis Pharmaceuticals Corporation (the "Company") held virtually on July 16, 2021 (the "Meeting"), stockholders holding and entitled to vote 74,873,343 shares of common stock of the Company, or approximately 50.29% of the outstanding shares on the record date for the Meeting, were present either by attendance via live webcast or by proxy. At the Meeting, the Company's stockholders voted on the proposals below, which are described in more detail in the Company's definitive proxy statement for the Meeting that was filed with the U.S. Securities and Exchange Commission on June 14, 2021 (the "Proxy Statement").

At the Meeting, stockholders:

(1) elected Howard C. Birndorf, Roshawn A. Blunt, Dennis J. Carlo, Ph.D., David J. Marguglio, and Richard C. Williams as directors to hold office until the 2022 Annual Meeting of Stockholders, or until such person's successor is duly elected and qualified, or until such person's earlier resignation, death, or removal;

(2) approved, on an advisory basis, the compensation paid to our named executive officers as disclosed in the Proxy Statement; and

(3) ratified the appointment of BDO USA, LLP, as our independent registered public accounting firm for the fiscal year ending December 31, 2021.

The following sets forth detailed information regarding the final results of the voting on the proposals at the Meeting:

1. Election of the five nominees to the board of directors:


                       Votes For  Votes Withheld Broker Non-Votes

Howard C. Birndorf 28,543,221 9,027,328 37,302,794 Roshawn A. Blunt 28,869,605 8,700,944 37,302,794 Dennis J. Carlo, Ph.D. 29,929,637 7,640,912 37,302,794 David J. Marguglio 31,524,893 6,045,656 37,302,794 Richard C. Williams 28,618,406 8,953,143 37,302,794

2. Approval, on a nonbinding advisory basis, of the compensation of the Company's named executive officers:

Votes For Votes Against Votes Abstaining Broker Non-Votes 17,821,561 17,812,097 1,936,891 37,302,794

3. Ratification of the selection of BDO USA, LLP, as independent registered public accounting firm for the year ending December 31, 2021:

Votes For Votes Against Votes Abstaining Broker Non-Votes 65,882,702 3,326,893 5,663,748

            0

© Edgar Online, source Glimpses

All news about ADAMIS PHARMACEUTICALS CORPORATION
09/13ADAMIS PHARMACEUTICALS : Departure of Directors of Certain Officers; Election of..
PU
09/13ADAMIS PHARMACEUTICALS CORP : Change in Directors or Principal Officers (form 8-..
AQ
09/13Adamis Pharmaceuticals Corporation Announces Resignation of Roshawn A. Blunt ..
CI
09/02ADAMIS PHARMACEUTICALS : Begins Dosing Patients in Phase 2/3 Trial of Tempol to ..
MT
09/02Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for T..
GL
09/02Adamis Pharmaceuticals Corporation Doses First Patients in Phase 2/3 Clinical..
CI
08/30NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
08/24ADAMIS PHARMACEUTICALS : 8-K (Form 8-K)
PU
08/24ADAMIS PHARMACEUTICALS CORP : Notice of Delisting or Failure to Satisfy a Contin..
AQ
08/24ADAMIS PHARMACEUTICALS : Names New CFO
MT
More news
Financials (USD)
Sales 2021 22,0 M - -
Net income 2021 -24,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,47x
Yield 2021 -
Capitalization 164 M 164 M -
Capi. / Sales 2021 7,44x
Capi. / Sales 2022 16,4x
Nbr of Employees 130
Free-Float 98,6%
Chart ADAMIS PHARMACEUTICALS CORPORATION
Duration : Period :
Adamis Pharmaceuticals Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAMIS PHARMACEUTICALS CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 1,10 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Dennis J. Carlo President, Chief Executive Officer & Director
David C. Benedicto Chief Financial & Accounting Officer
Richard C. Williams Chairman
Ronald B. Moss Chief Medical Officer
Karen K. Daniels Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ADAMIS PHARMACEUTICALS CORPORATION126.76%164
JOHNSON & JOHNSON4.98%434 939
ROCHE HOLDING AG11.70%327 062
PFIZER, INC.21.62%249 329
NOVO NORDISK A/S51.34%233 887
ELI LILLY AND COMPANY36.84%209 456